×
About 578,888 results

WFH Guidelines for the Management of Hemophilia, 3rd edition
https://onlinelibrary.wiley.com/doi/10.1111/hae.14046
Haemophilia

Aug 3rd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 2012, tremendous advances have been made in several aspects of the management of hemophilia. These include genetic assessment as well as therapy with ma...

Researchers gain insight into factors influencing immunotherapy response in kidney cancer
https://www.healio.com/news/hematology-oncology/20200710/researchers-gain-insight-into-factors-influencing-immunotherapy-response-in-kidney-cancer

Jul 10th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...

New Kidney Cancer Research From the ASCO20 Virtual Scientific Program Demonstrates an Exciting, Evolving Field
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200216/full/

Jun 25th, 2020 - There used to be a paucity of options for managing advanced renal cell cancer (RCC) with a high toxicity profile including traditional chemotherapy, interferon, and interleukins. With the advent of tyrosine kinase inhibitors (TKIs) in 2007 followed by immunotherapy over the past few years, a paradigm shift emerged in managing this increasingly prevalent disease with its associated high morbidit...

Expanding the role of PARP inhibitors in breast cancer
https://www.mdedge.com/hematology-oncology/article/223054/breast-cancer/expanding-role-parp-inhibitors-breast-cancer

May 31st, 2020 - For patients with BRCA-like triple-negative breast cancer (TNBC), adding veliparib to cisplatin chemotherapy may extend survival, based on results from the phase 3 SWOG S1416 trial.

Autoantibodies May Predict Disease Response in Metastasized Melanoma Treated With Checkpoint Inhibitors
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200204/full/

May 30th, 2020 - There is a diverse and broad autoantibody response to tumor and autoimmune disease antigens in melanoma treated with checkpoint inhibitors (CPIs). Results from a recent study presented during the ASCO20 Virtual Scientific Meeting show that some of those autoantibodies correlate to clinical outcomes and immune-related adverse events (irAEs; Abstract 10011).

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
https://ascopost.com/news/may-2020/study-finds-patients-with-lung-cancer-infected-with-covid-19-recently-treated-with-chemotherapy-at-higher-risk-of-death/

May 29th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian Cancer
https://www.targetedonc.com/view/parp-inhibition-improves-outcomes-in-patients-with-brca-mutated-ovarian-cancer

May 29th, 2020 - David O'Malley, MD, professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine, and director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.

Addition of Ublituximab to Ibrutinib Appears Safe and Effective for Patients With High-Risk Chronic Lymphocytic Leukemia
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200124/full/

May 13th, 2020 - Although chronic lymphocytic leukemia (CLL) has a relatively high 5-year survival rate (85% for people age 20 and older), effective treatments for advanced disease are still needed. Use of combination or monotherapy Bruton’s tyrosine kinase (BTK) inhibitors has shown promise for people with CLL, with the BTK inhibitor ibrutinib now considered a standard of care for patients of any age. However,...

Combination Immunotherapy Could Be a Potential Treatment Option for Rare Gynecologic Cancers, Pending Randomized Trial Validation
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200122/full/

May 13th, 2020 - The novel combination of immune checkpoint inhibitors ipilimumab and nivolumab may offer patients with rare gynecologic neoplasms the opportunity for improved outcomes, according to a new study (Abstract 6091) that will be presented during the ASCO20 Virtual Scientific Program.

Antihypertensive drugs and risk of COVID-19?
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30153-3/fulltext
The Lancet Respiratory Medicine;

Mar 26th, 2020 - Lei Fang and colleagues1 suggest that clinicians should consider withholding angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) because of a potential increased risk of worse clinical outcomes in patients with coronavirus disease 2019 (COVID-19), and they suggest calcium channel blockers as an alternative. The hypothesis behind this suggestion is that the e...

Statins and the COVID-19 main protease: in silico evidence on direct interaction
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212226/
Archives of Medical Science; Reiner Z

Apr 25th, 2020 - No proven drug and no immunisation are yet available for COVID-19 disease. The SARS-CoV-2 main protease (Mpro), a key coronavirus enzyme, which is a potential drug target, has been successfully crystallised. There is evidence suggesting that statins exert anti-viral activity and may block the infectivity of enveloped viruses. The aim of this study was to assess whether statins are potential COV...

Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742232/
PLOS Medicine; Ruscitti P

Sep 16th, 2019 - The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we aimed at investigating whether interleukin-1 (IL-1) inhibition with anakinra, a recombinant human IL-1 receptor antagonist, could improve both glycaemic and inflammatory parameters in participants with RA and T2D compared wit...

The Hypotensive Role of Acupuncture in Hypertension: Clinical Study and Mechanistic Study
https://www.frontiersin.org/articles/10.3389/fnagi.2020.00138/full

As a component of traditional Chinese medicine (TCM), acupuncture has the potential to lower blood pressure (BP) in patients with hypertension. Emerging evidence indicates that the acupuncture-induced inhibition of high BP occurs through the activation of the pathway in the afferent, central, and efferent pathways. An increasing number of studies have demonstrated that acupuncture not only acti...

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
https://www.nejm.org/doi/full/10.1056/NEJMoa2007621
The New England Journal of Medicine;

Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical context.

Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S125–S150
https://care.diabetesjournals.org/content/early/2021/06/15/dc21-ad09a
Diabetes Care; American Diabetes Association® (ADA)

Jun 15th, 2021 - Section 10, Cardiovascular Disease and Risk Management, of the Standards of Medical Care in Diabetes—2021 has been annotated to include evidence from trials of SGLT2 inhibitors including the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV), Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal ...

Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1758791
Journal of Biomolecular Structure and Dynamics;

In December 2019, COVID-19 epidemic was described in Wuhan, China, and the infection has spread widely affecting hundreds of thousands. Herein, an effort was made to identify commercially available drugs in order to repurpose them against coronavirus by the means of structure-based virtual screening. In addition, ZINC15 library was used to identify novel leads against main proteases. Human TMPR...

Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations
https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1758790
Journal of Biomolecular Structure and Dynamics;

The new Corona-virus, recently called the severe acute respiratory syndrome Coronavirus (SARS-CoV-2) appears for the first time in China and more precisely in Wuhan (December 2019). This disease can be fatal. Seniors, and people with other medical conditions (diabetes, heart disease…), may be more vulnerable and become seriously ill. This is why research into drugs to treat this infection remai...

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
https://science.sciencemag.org/content/early/2021/01/22/science.abf4058
Science White KM, Rosales R et. al.

Jan 25th, 2021 - SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (IC90 = 0.88 nM) 27.5-fold more potent than remdesivir against SARS-CoV-2 in vitro, with limited toxicity in cell culture.

EETs/sEHi alleviates nociception by blocking the crosslink between endoplasmic reticulu...
https://doi.org/10.1186/s12974-021-02255-3 10.1016/j.jns.2009.04.030 10.1016/S1474-4422(10)70143-5 10.1016/S1474-4422(09)70176-0 10.1213/ane.0b013e31819d644c 10.1111/obr.12673 10.1113/EP086274 10.1016/j.cell.2016.12.004 10.1016/j.cell.2010.02.034 10.1038/nrm3270 10.1016/j.redox.2018.11.005 10.1126/science.1146361 10.5607/en.2014.23.4.372 10.2147/JPR.S125805 10.3389/fnins.2020.00090 10.1016/j.ejphar.2019.172714 10.1523/JNEUROSCI.5358-09.2010 10.1074/jbc.M114.550517 10.3389/fimmu.2017.01014 10.1097/ALN.0000000000002130 10.1016/j.lfs.2006.07.031 10.1073/pnas.0809765105 10.1073/pnas.1815746116 10.1016/j.prostaglandins.2011.08.001 10.1016/j.jpain.2018.11.006 10.1096/fj.14-262055 10.3389/fphar.2019.00420 10.1016/j.pharmthera.2017.05.004 10.1212/WNL.48.5.1196 10.1016/j.cell.2008.07.021 10.1002/jcb.28761 10.1080/15548627.2015.1121360 10.1111/j.1582-4934.2011.01374.x 10.1038/nrneurol.2017.99 10.1097/ALN.0000000000003078 10.1016/j.neuroscience.2018.08.005 10.1073/pnas.1510137112 10.1186/s12974-019-1524-2 10.1186/s13024-017-0183-y 10.1161/HYPERTENSIONAHA.115.06329 10.1152/ajpheart.00362.2016 10.1126/science.287.5453.664 10.1038/ncb0502-e131 10.1016/j.phrs.2020.104923 10.4103/1673-5374.202925
Journal of Neuroinflammation; Liu T, Li T et. al.

Sep 18th, 2021 - Central post-stroke pain (CPSP) is a chronic and intolerable neuropathic pain syndrome following a cerebral vascular insult, which negatively impacts the quality of life of stroke survivors but currently lacks efficacious treatments. Though its underlying mechanism remains unclear, clinical features of hyperalgesia and allodynia indicate central sensitization due to excessive neuroinflammation....

High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better.
https://doi.org/10.1016/j.mayocp.2021.02.032
Mayo Clinic Proceedings; Grundy SM, Stone NJ et. al.

Sep 18th, 2021 - Review of the US and European literature indicates that most patients at high risk for atherosclerotic cardiovascular disease (ASCVD are not treated with high-intensity statins, despite strong clinical-trial evidence of maximal statin benefit. High-intensity statins are recommended for 2 categories of patients: those with ASCVD (secondary prevention) and high-risk patients without clinical ASCV...